side effects of glp-1 medications Peptide/GLP-1 Complications: 11 Hidden Risks and You Must Know Why do patients stop GLP-1

not available for commercial use in U.S.), dulaglutide (Trulicity, Eli Lilly), oral semaglutide (Rybelsus, Novo Nordisk) and efpeglenatide (Sanofi) researchers also found that human and exendin-based GLP-1 receptor agonists reduce risk for all-cause mortality, hospitalization for heart failure, and a composite kidney outcome of development of new-onset macroalbuminuria, decline in estimated glomerular filtration rate or increase in creatinine, renal replacement therapy or renal death

Carroll RC, Beattie EC, Xia H, Luscher C, Altschuler Y, Nicoll RA et al (1999)

Cholesterol possesses a strong membrane fusion capacity, facilitating the internalization of NADs and their entry into the cytoplasm

A single medication that addresses the reward dysregulation underlying both could simplify treatment, improve compliance (patients are motivated by visible weight loss), and reduce the sense of being pulled in multiple directions that so many patients describe